Phase I/II Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 31 Mar 2017
At a glance
- Drugs ONC 201 (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 28 Mar 2017 Status changed from active, no longer recruiting to recruiting.
- 22 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 18 Nov 2016 Planned number of patients changed from 150 to 60.